Fuso Pharmaceutical Industries, Ltd., commonly referred to as Fuso Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1950, the company has made significant strides in developing innovative healthcare solutions, primarily focusing on prescription pharmaceuticals and over-the-counter products. With a strong operational presence in Asia and beyond, Fuso Pharma is renowned for its commitment to quality and research-driven approaches. The company’s core offerings include a diverse range of therapeutic agents, particularly in the fields of oncology and infectious diseases, distinguished by their efficacy and safety profiles. Fuso Pharmaceutical Industries has achieved notable recognition within the market, positioning itself as a trusted name in healthcare. Its dedication to advancing medical science and improving patient outcomes underscores its pivotal role in the global pharmaceutical landscape.
How does Fuso Pharmaceutical Industries,Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fuso Pharmaceutical Industries,Ltd.'s score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fuso Pharmaceutical Industries, Ltd., headquartered in Japan, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Fuso Pharmaceutical Industries, Ltd. does not inherit emissions data from any parent or related organizations, nor does it have any cascading targets from initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and climate commitments. However, without specific data or targets, it is unclear how Fuso Pharmaceutical Industries, Ltd. aligns with these industry trends.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fuso Pharmaceutical Industries,Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.